FDA-Genetically Engineered Generic Drugs to Be Unleashed Without Mandatory Testing

Under the healthcare reform of 2010, the FDA was given the authority to regulate generic versions of genetically engineered (GE) drugs.


The government is really boosting the GE biotech drug market which was valued at $243 million in 2010 and is expected to grow to $3.7 billion in sales by 2015. The government says that GE generic biosimilars will save them $25 billion over 10 years.

Ironically, GE biotech drug makers even argued against GE biosimilar generic drugs, saying that the formulas were too complex to duplicate, but meanwhile they are simultaneously pursuing copy-cats of their competitor’s GE drugs.

There is a lot of money to be made in the GE drug market. For example, Roche’s Avastin (a GE biotech cancer drug) costs $100,000 a year. Amazingly, people are paying these high prices of cancer drugs that have been found in the past to be not only ineffective, but kill the patient more quickly.

[link to www.activistpost.com]


peace